Which has stronger earnings and valuation, AMGN or ABBV?

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.75 $7.71B $16.09 24.29 AbbVie $61.16B 7.19 $4.23B $3.54 70.32

Is AMGN or ABBV more profitable?

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 22.95% 124.14% 13.18% AbbVie 9.80% -422.07% 14.34%

Does the media prefer AMGN or ABBV?

In the previous week, AbbVie had 75 more articles in the media than Amgen. MarketBeat recorded 132 mentions for AbbVie and 57 mentions for Amgen. AbbVie's average media sentiment score of 1.39 beat Amgen's score of 0.42 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 23 Very Positive mention(s) 6 Positive mention(s) 13 Neutral mention(s) 11 Negative mention(s) 3 Very Negative mention(s) Neutral AbbVie 109 Very Positive mention(s) 8 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Is GILD or ABBV more profitable?

AbbVie has a net margin of 9.80% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% AbbVie 9.80% -422.07% 14.34%

Does the media prefer GILD or ABBV?

In the previous week, AbbVie had 91 more articles in the media than Gilead Sciences. MarketBeat recorded 132 mentions for AbbVie and 41 mentions for Gilead Sciences. AbbVie's average media sentiment score of 1.39 beat Gilead Sciences' score of 1.04 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 26 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive AbbVie 109 Very Positive mention(s) 8 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Which has better valuation & earnings, MRNA or ABBV?

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $2.21B 24.84 -$2.82B -$7.99 N/A AbbVie $61.16B 7.19 $4.23B $3.54 70.32

Is MRNA or ABBV more profitable?

AbbVie has a net margin of 9.80% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% AbbVie 9.80% -422.07% 14.34%

Does the media refer more to MRNA or ABBV?

In the previous week, AbbVie had 88 more articles in the media than Moderna. MarketBeat recorded 132 mentions for AbbVie and 44 mentions for Moderna. AbbVie's average media sentiment score of 1.39 beat Moderna's score of 0.50 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 12 Positive mention(s) 9 Neutral mention(s) 5 Negative mention(s) 4 Very Negative mention(s) Neutral AbbVie 109 Very Positive mention(s) 8 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Does the media refer more to ABBV or ABT?

In the previous week, AbbVie had 61 more articles in the media than Abbott Laboratories. MarketBeat recorded 132 mentions for AbbVie and 71 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.47 beat AbbVie's score of 1.39 indicating that Abbott Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 109 Very Positive mention(s) 8 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive Abbott Laboratories 60 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has higher earnings and valuation, AZN or ABBV?

Astrazeneca has higher revenue and earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $61.37B 3.99 $10.23B $6.69 23.57 AbbVie $61.16B 7.19 $4.23B $3.54 70.32

Is AZN or ABBV more profitable?

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% AbbVie 9.80% -422.07% 14.34%

Does the media prefer AZN or ABBV?

In the previous week, AbbVie had 115 more articles in the media than Astrazeneca. MarketBeat recorded 132 mentions for AbbVie and 17 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.39 beat Astrazeneca's score of 0.77 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive AbbVie 109 Very Positive mention(s) 8 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

AbbVie (ABBV) Competitors

$249.14 +0.36 (+0.14%)

As of 01:28 PM Eastern

Compare

ABBV vs. AMGN, GILD, MRNA, ABT, and AZN

Should you buy AbbVie stock or one of its competitors? AbbVie's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), and Astrazeneca (AZN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does AbbVie compare to Amgen?

Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, AbbVie had 75 more articles in the media than Amgen. MarketBeat recorded 132 mentions for AbbVie and 57 mentions for Amgen. AbbVie's average media sentiment score of 1.39 beat Amgen's score of 0.42 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	23 Very Positive mention(s)	6 Positive mention(s)	13 Neutral mention(s)	11 Negative mention(s)	3 Very Negative mention(s)	Neutral
AbbVie	109 Very Positive mention(s)	8 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Amgen presently has a consensus price target of $381.68, suggesting a potential downside of 2.35%. AbbVie has a consensus price target of $275.95, suggesting a potential upside of 10.85%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	14 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.37
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.75	$7.71B	$16.09	24.29
AbbVie	$61.16B	7.19	$4.23B	$3.54	70.32

76.5% of Amgen shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.6%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Amgen pays out 62.6% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
AbbVie	9.80%	-422.07%	14.34%

Summary

AbbVie beats Amgen on 12 of the 20 factors compared between the two stocks.

How does AbbVie compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

AbbVie has a net margin of 9.80% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
AbbVie	9.80%	-422.07%	14.34%

Gilead Sciences has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, AbbVie had 91 more articles in the media than Gilead Sciences. MarketBeat recorded 132 mentions for AbbVie and 41 mentions for Gilead Sciences. AbbVie's average media sentiment score of 1.39 beat Gilead Sciences' score of 1.04 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	26 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
AbbVie	109 Very Positive mention(s)	8 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Gilead Sciences has higher earnings, but lower revenue than AbbVie. Gilead Sciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	6.15	$8.51B	-$2.67	N/A
AbbVie	$61.16B	7.19	$4.23B	$3.54	70.32

Gilead Sciences currently has a consensus price target of $158.04, suggesting a potential upside of 8.26%. AbbVie has a consensus price target of $275.95, suggesting a potential upside of 10.85%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.86
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

AbbVie beats Gilead Sciences on 13 of the 20 factors compared between the two stocks.

How does AbbVie compare to Moderna?

Moderna (NASDAQ:MRNA) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

In the previous week, AbbVie had 88 more articles in the media than Moderna. MarketBeat recorded 132 mentions for AbbVie and 44 mentions for Moderna. AbbVie's average media sentiment score of 1.39 beat Moderna's score of 0.50 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	12 Positive mention(s)	9 Neutral mention(s)	5 Negative mention(s)	4 Very Negative mention(s)	Neutral
AbbVie	109 Very Positive mention(s)	8 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

75.3% of Moderna shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.21B	24.84	-$2.82B	-$7.99	N/A
AbbVie	$61.16B	7.19	$4.23B	$3.54	70.32

Moderna presently has a consensus target price of $76.72, suggesting a potential downside of 44.20%. AbbVie has a consensus target price of $275.95, suggesting a potential upside of 10.85%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

AbbVie has a net margin of 9.80% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
AbbVie	9.80%	-422.07%	14.34%

Moderna has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Summary

AbbVie beats Moderna on 12 of the 17 factors compared between the two stocks.

How does AbbVie compare to Abbott Laboratories?

AbbVie (NYSE:ABBV) and Abbott Laboratories (NYSE:ABT) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Abbott Laboratories has a net margin of 11.65% compared to AbbVie's net margin of 9.80%. Abbott Laboratories' return on equity of 17.69% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Abbott Laboratories	11.65%	17.69%	9.44%

Abbott Laboratories has lower revenue, but higher earnings than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.19	$4.23B	$3.54	70.32
Abbott Laboratories	$46.59B	3.93	$6.52B	$3.09	34.21

AbbVie has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.4%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories pays out 81.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 53 consecutive years and Abbott Laboratories has increased its dividend for 54 consecutive years.

70.2% of AbbVie shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, AbbVie had 61 more articles in the media than Abbott Laboratories. MarketBeat recorded 132 mentions for AbbVie and 71 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.47 beat AbbVie's score of 1.39 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	109 Very Positive mention(s)	8 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Abbott Laboratories	60 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

AbbVie presently has a consensus price target of $275.95, indicating a potential upside of 10.85%. Abbott Laboratories has a consensus price target of $119.50, indicating a potential upside of 13.04%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	20 Buy rating(s)	3 Strong Buy rating(s)	2.96

Summary

Abbott Laboratories beats AbbVie on 13 of the 20 factors compared between the two stocks.

How does AbbVie compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, AbbVie had 115 more articles in the media than Astrazeneca. MarketBeat recorded 132 mentions for AbbVie and 17 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.39 beat Astrazeneca's score of 0.77 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	12 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
AbbVie	109 Very Positive mention(s)	8 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Astrazeneca has higher revenue and earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$61.37B	3.99	$10.23B	$6.69	23.57
AbbVie	$61.16B	7.19	$4.23B	$3.54	70.32

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.8%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Astrazeneca currently has a consensus price target of $206.67, indicating a potential upside of 31.05%. AbbVie has a consensus price target of $275.95, indicating a potential upside of 10.85%. Given Astrazeneca's higher probable upside, equities research analysts clearly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
AbbVie	9.80%	-422.07%	14.34%

Astrazeneca has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Summary

AbbVie beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

Get AbbVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABBV vs. The Competition

Export

Metric	AbbVie	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$439.90B	$3.87B	$7.16B	$23.31B
Dividend Yield	2.70%	3.60%	2.54%	3.73%
P/E Ratio	70.33	13.22	271.88	28.78
Price / Sales	7.19	1,619.38	700.01	96.26
Price / Cash	16.93	108.60	77.07	33.53
Price / Book	-136.03	16.21	10.86	4.76
Net Income	$4.23B	-$22.81M	$3.48B	$1.07B
7 Day Performance	-4.81%	0.56%	-0.82%	-0.84%
1 Month Performance	1.27%	5.75%	2.80%	-2.18%
1 Year Performance	18.28%	46.72%	21.60%	11.80%

AbbVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABBV AbbVie	4.684 of 5 stars	$249.14 +0.1%	$275.95 +10.8%	+18.5%	$440.10B	$61.16B	70.37	57,000	Positive News Analyst Forecast
AMGN Amgen	3.9462 of 5 stars	$437.19 -1.6%	$381.68 -12.7%	+40.3%	$236.39B	$38.10B	27.18	31,500	Trending News Analyst Forecast
GILD Gilead Sciences	3.8796 of 5 stars	$150.02 -0.8%	$158.04 +5.3%	+26.5%	$186.03B	$30.46B	N/A	17,000	Positive News
MRNA Moderna	1.4714 of 5 stars	$142.25 -4.4%	$76.72 -46.1%	+465.2%	$56.67B	$1.94B	N/A	4,700
ABT Abbott Laboratories	4.8728 of 5 stars	$109.25 +0.4%	$119.50 +9.4%	-20.1%	$188.94B	$44.33B	35.34	115,000	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABBV) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Competitors